Aurobindo Pharma FY26 Revenue Tops Rs 33,600 Cr, Europe Sales Surge 30%

The company also achieved a major milestone with its European business crossing €1 billion in revenues during FY26. European revenue for the quarter increased 30.2 per cent year-on-year to Rs 2,795 crore or EUR 261 million.

For FY26, consolidated revenue from operations stood at Rs 33,653 crore compared to Rs 31,724 crore in FY25, registering 6.1 per cent growth. Net profit for the year increased marginally to Rs 3,503 crore from Rs 3,484 crore last fiscal.

Quarterly EBITDA before forex, other income and exceptional items stood at Rs 1,801 crore, up 0.5 per cent year-on-year, while EBITDA margin came at 20.3 per cent. EBITDA before R&D stood at Rs 2,165 crore with margin of 24.5 per cent.

Research and development expenditure, including depreciation, stood at Rs 400 crore during the quarter, accounting for 4.5 per cent of revenues.The company maintained a strong net cash position as of March 31, 2026 despite payment for acquisition of Khandelwal Laboratories’ non-oncology business valued at USD 317 million. Free cash flows generated during the quarter stood at USD 35 million, while basic and diluted EPS came at Rs 15.86 per share.

Commenting on the performance, Vice-Chairman and Managing Director K Nithyananda Reddy said the company’s results reflected resilience of its business model, extensive product portfolio, consistent volumes, improved operating efficiencies and disciplined execution. He added that ongoing investments in capacity expansion and stabilization of recently commercialized facilities would support sustainable long-term growth.

Aurobindo Pharma’s US formulations revenue declined 13 per cent year-on-year to Rs 3,543 crore primarily due to lower transient sales, accounting for 40 per cent of consolidated revenue. However, Europe formulations business recorded robust performance across key markets with 30.2 per cent growth.

Growth Markets formulations revenue rose 24.7 per cent year-on-year to Rs 980 crore driven by strong performance in key markets, while ARV formulations revenue increased 6.4 per cent to Rs 328 crore.

API revenue also grew 12.9 per cent year-on-year to Rs 1,208 crore, contributing 13.6 per cent to consolidated revenue. In USD terms, API revenue increased 6.9 per cent to USD 132 million. The company stated that domestic formulation sales stood at Rs 76 crore during Q4 FY26 and Rs 302 crore for the full financial year.

Aurobindo Pharma further informed that formulations revenue increased 4.6 per cent year-on-year to Rs 7,646 crore during the quarter. As of March 31, 2026, the company had cumulatively filed 888 ANDAs with the USFDA and received 728 final approvals along with 35 tentative approvals. During Q4 FY26, the company launched 12 products and received final approval for nine ANDAs from the USFDA.

The approved products included Aripiprazole Orally Disintegrating Tablets USP, Cefixime Capsules, Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, Siponimod Tablets, Clindamycin Phosphate Gel USP, Everolimus Tablets, Citalopram Capsules, Betamethasone Dipropionate Cream USP and Mesna Injection.

The company also reported cumulative regulatory filings of 322 US DMFs, 5,023 formulations dossiers in advanced markets and 4,114 API filings in regulated markets globally. Aurobindo Pharma currently operates 31 manufacturing and packaging facilities approved by global regulators including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC and Brazil ANVISA.

According to the company’s press release, Aurobindo Pharma will host its earnings call at 8:30 AM IST on May 22, 2026 to discuss financial performance and operational updates.